GLP-1 drugs pose an existential threat to CPAP-makers. ResMed is currently experiencing temporary tailwinds before potential long-term headwinds. ResMed (NYSE: RMD) finds itself in an investment limbo ...
“Our fiscal year 2026 is off to a strong start, with first-quarter performance reflecting continued progress toward our mission of helping people sleep better, breathe better and live longer and ...
Another ASX share that could be a top buy with the $10,000 is ResMed. It is a global leader in sleep apnoea treatment, with a strong portfolio of devices and software solutions that help millions of ...
“Physicians will get prescriptions that they will give to patients. The patients will call us. And we will give each patient ...
12d
This Hamilton neurosurgeon brings livestreamed surgeries straight to the laptops of medical students
Students can toggle between several views of the surgery in progress, such as POVs, image guidance screens and endoscopes.
The provincial government has ordered the Saskatchewan Health Authority to stop using scheduling software that health-care ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback